Frank S Czerwiec Jr. MD PhD (He/Him)
[Pronunciation: Chair-V-etz]
Diabetes, Lipid Metabolism
Chief Medical Officcer, Sparrow Pharma
Join to View Full Profile
2675 S Bayshore DrSuite 1103S Clinical DevelopmentCoconut Grove, FL 33133
Dr. Czerwiec is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1994 - 1997
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1990 - 1994
University of Miami Leonard M. Miller School of MedicineClass of 1990
Certifications & Licensure
MD State Medical License 1994 - 2026
VA State Medical License 1994 - 2026
Clinical Trials
- Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Start of enrollment: 2007 Jan 01
- Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Start of enrollment: 2010 Oct 01
- Tolvaptan Extension Study in Participants With ADPKD Start of enrollment: 2010 May 26
- Join now to see all
Publications & Presentations
PubMed
- Fracture risk by cortisol excess status in patients with adrenal incidentalomas: a population-based cohort study.Annette L Adams, In-Lu Amy Liu, Iris Anne C Reyes, Hina Chowdhry, Richard Contreras
JBMR Plus. 2025-05-01 - 1 citationsDexamethasone Suppression Testing in a Contemporary Cohort with Adrenal Incidentalomas in Two U.S. Integrated Healthcare Systems.Mackenzie Crawford, Bennett McDonald, Wansu Chen, Hina Chowdhry, Richard Contreras
Biomedicines. 2023-11-28 - 11 citationsCurrent Challenges and Perspectives on Developing a Clinical Trial Design for ADPKD.Craig Ostroff, Ronald D Perrone, Frank S Czerwiec
Clinical Journal of the American Society of Nephrology. 2022-10-01
Press Mentions
Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 DiabetesSeptember 24th, 2025- Sparrow Pharmaceuticals Announces Completion of Phase 2 Trial and FDA Orphan Drug Designation of Clofutriben for Endogenous Cushing’s SyndromeOctober 28th, 2024
- Chutes & Ladders—J&J CEO Gorsky to Step Aside, Handing World's Largest Pharma to COVID-19 Navigator DuatoAugust 20th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
